绿叶制药抗抑郁1类创新药(LY03021)获准开展临床试验

格隆汇资讯11-11

格隆汇11月11日丨绿叶制药(02186.HK)宣布，集团的1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，拟用于治疗抑郁症。LY03021为去甲肾上腺素转运体(“NET”)╱多巴胺转运体("DAT")抑制剂、γ－氨基丁酸A受体正向变构调节剂(GABAAR PAM)。该产品基于集团新分子实体╱新治疗实体技术平台(NCE/NTE)自主开发，是全新的三靶点作用机制...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482624042?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-11 12:19","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482624042","market":"hk","top_or_hot":-1,"title":"绿叶制药抗抑郁1类创新药(LY03021)获准开展临床试验","media":"格隆汇资讯","content":"<div>\n<p>格隆汇11月11日丨绿叶制药(02186.HK)宣布，集团的1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，拟用于治疗抑郁症。LY03021为去甲肾上腺素转运体(“NET”)╱多巴胺转运体(\"DAT\")抑制剂、γ－氨基丁酸A受体正向变构调节剂(GABAAR PAM)。该产品基于集团新分子实体╱新治疗实体技术平台(NCE/NTE)自主开发，是全新的三靶点作用机制...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111121904abb4a247&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>绿叶制药抗抑郁1类创新药(LY03021)获准开展临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n绿叶制药抗抑郁1类创新药(LY03021)获准开展临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 12:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111121904abb4a247&s=b><strong>格隆汇资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇11月11日丨绿叶制药(02186.HK)宣布，集团的1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，拟用于治疗抑郁症。LY03021为去甲肾上腺素转运体(“NET”)╱多巴胺转运体(\"DAT\")抑制剂、γ－氨基丁酸A受体正向变构调节剂(GABAAR PAM)。该产品基于集团新分子实体╱新治疗实体技术平台(NCE/NTE)自主开发，是全新的三靶点作用机制...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111121904abb4a247&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111121904abb4a247&s=b","article_id":"2482624042","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111121904abb4a247&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482624042","pubTimestamp":1731298741,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇11月11日丨绿叶制药宣布，集团的1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，拟用于治疗抑郁症。抑郁症是由各种原因引起的，以显着和持久的抑郁症状群为主要临床特征，并损害社会功能的一类心境障碍。现有抗抑郁药总体有效率和治愈率低，且普遍存在起效较慢、残留症状多、复发风险高、不良反应多等局限。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Luye Pharma's antidepressant class 1 innovative drug (LY03021) was approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1,"03347":1,"06978":1},"content_text":"格隆汇11月11日丨绿叶制药(02186.HK)宣布，集团的1类创新药LY03021已获得中国国家药品监督管理局药品审评中心批准开展临床试验，拟用于治疗抑郁症。LY03021为去甲肾上腺素转运体(“NET”)╱多巴胺转运体(\"DAT\")抑制剂、γ－氨基丁酸A受体正向变构调节剂(GABAAR PAM)。该产品基于集团新分子实体╱新治疗实体技术平台(NCE/NTE)自主开发，是全新的三靶点作用机制抗抑郁药物，具有同类首创(First-in-Class)的潜质。据公司所知，目前尚未检索到相同机制的产品在研。抑郁症是由各种原因引起的，以显着和持久的抑郁症状群为主要临床特征，并损害社会功能的一类心境障碍。流行病学数据显示：我国抑郁症患病呈上升趋势，抑郁症的终生患病率为3.4%、12个月患病率为2.1%。抑郁症伴随高复发率、高自杀率、高致残率，严重影响患者、其家庭和社会。现有抗抑郁药总体有效率和治愈率低，且普遍存在起效较慢、残留症状多、复发风险高、不良反应多等局限。因此，如何快速有效的控制抑郁症的临床症状，进一步改善治疗效果和预后成为当下抗抑郁药物研发中需要攻克的难题。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482624042"}